FindTrial
Sign In

A retrospective study to investigate PD-L1 expression before and after EGFR-TKI therapy and its relationship with EGFR-TKI resistance mechanism in EGFR mutation-positive advanced recurrent non- squamous non-small-cell lung cancer

A retrospective study to investigate PD-L1 expression before and after EGFR-TKI therapy and its relationship with EGFR-TKI resistance mechanism in EGFR mutation-positive advanced recurrent non- squamous non-small-cell lung cancer - A retrospective study to investigate PD-L1 expression before and after EGFR-TKI therapy and its relationship with EGFR-TKI resistance mechanism in EGFR mutation-positive advanced recurrent non- squamous non-small-cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000033993
Enrollment
80
Registered
2018-09-05
Start date
2017-11-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR mutation-positive advanced recurrent non-squamous non-small-cell lung cancer

Interventions

None listed

Sponsors

Kindai university, Faculty of Medicine, Department of Medical Oncology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Aged 20 years or older 2)Patients with pathologically confirmed non-squamous non-small-cell lung cancer 3)Patients at stage IIIB/IV (including those who had recurrence after definitive treatment such as surgery or radiotherapy) 4)Patients with confirmed EGFR mutation (any variant type) 5)Patients who were treated at Department of Medical Oncology, Kinki University Faculty of Medicine or a joint study institution 6)Patients whose tumor tissue at baseline available for this study 7)Patients who were confirmed to have disease progression during EGFR-TKI treatment and whose tumor tissues have been obtained at subsequent biopsy 8)As for the patients who received Osimertinib, T790M mutation must be detected during the previous conventional EGFR-TKIs

Exclusion criteria

Exclusion criteria: Not established

Design outcomes

Primary

MeasureTime frame
The changes in PD-L1 expression level, CD73, TILs, and nonsynonymous mutation burden before and after EGFR-TKIs treatment—

Countries

Japan

Contacts

Public ContactKoji Haratani

Kindai University, Faculty of Medicine Department of Medical Oncology

haratani_k@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026